Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
3.095
+0.035 (1.14%)
Nov 21, 2024, 11:43 AM EST - Market open

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois.

The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome.

It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies.

The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings logo
Country United States
Founded 2005
IPO Date Jun 21, 2018
Industry Biotechnology
Sector Healthcare
Employees 377
CEO John Shannon

Contact Details

Address:
180 North LaSalle Street, Suite 1600
Chicago, Illinois 60601
United States
Phone 844 445 5704
Website xerispharma.com

Stock Details

Ticker Symbol XERS
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001346302
CUSIP Number 98422E103
ISIN Number US98422E1038
Employer ID 20-3352427
SIC Code 2834

Key Executives

Name Position
John P. Shannon Chief Executive Officer and Director
Steven M. Pieper Chief Financial Officer
Beth P. Hecht J.D. Chief Legal Officer and Corporate Secretary
Dr. Kenneth E. Johnson Pharm. D., Pharm.D. Senior Vice President of Global Development and Medical Affairs
Allison Wey Senior Vice President of Investor Relations and Corporate Communications
Brian Conner SVice President of Quality and Chief Compliance and Risk Officer
Kendal Korte Senior Vice President of Human Resources
Kevin McCulloch Chief Commercial Officer

Latest SEC Filings

Date Type Title
Feb 14, 2022 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Oct 15, 2021 15-12B Securities registration termination
Oct 6, 2021 EFFECT Notice of Effectiveness
Oct 5, 2021 25-NSE Filing
Oct 5, 2021 POS AM Post-Effective amendments for registration statement
Oct 5, 2021 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 5, 2021 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 5, 2021 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 5, 2021 S-8 POS Securities to be offered to employees in employee benefit plans, post-effective amendments
Oct 5, 2021 8-K Current Report